Formulation of influenza T cell peptides : in search of a universal influenza vaccine

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Unknown venue

• Publication date

  2015-10-20

• Fields of study

  Biology, Medicine

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Safety and immunogenicity of influenza whole inactivated virus vaccines: A phase I randomized clinical trial

  2015cited by this paper
• Predicting the influence of liposomal lipid composition on liposome size, zeta potential and liposome-induced dendritic cell maturation using a design of experiments approach.

  2015cited by this paper
• Comparison of Pandemrix and Arepanrix, two pH1N1 AS03-adjuvanted vaccines differentially associated with narcolepsy development.

  2015cited by this paper
• Development of Cross-Protective Influenza A Vaccines Based on Cellular Responses

  2015cited by this paper
• Current and next generation influenza vaccines: Formulation and production strategies.

  2015cited by this paper
• Phase 1 clinical study with Bioneedles, a delivery platform for biopharmaceuticals.

  2015cited by this paper
• A novel peptide-based pan-influenza A vaccine: a double blind, randomised clinical trial of immunogenicity and safety.

  2015cited by this paper
• Discovering protective CD8 T cell epitopes--no single immunologic property predicts it!

  2015cited by this paper
• Physical detection of influenza A epitopes identifies a stealth subset on human lung epithelium evading natural CD8 immunity

  2015cited by this paper
• An overview of bioinformatics tools for epitope prediction: Implications on vaccine development

  2015cited by this paper
• Alternative delivery of a thermostable inactivated polio vaccine.

  2015cited by this paper
• The impact of size on particulate vaccine adjuvants.

  2014cited by this paper
• Modified Vaccinia Virus Ankara (MVA) as Production Platform for Vaccines against Influenza and Other Viral Respiratory Diseases

  2014cited by this paper
• A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human.

  2014cited by this paper
• Mucosal Polyinosinic-Polycytidylic Acid Improves Protection Elicited by Replicating Influenza Vaccines via Enhanced Dendritic Cell Function and T Cell Immunity

  2014cited by this paper
• Low 2012–13 Influenza Vaccine Effectiveness Associated with Mutation in the Egg-Adapted H3N2 Vaccine Strain Not Antigenic Drift in Circulating Viruses

  2014cited by this paper
• Membrane-bound IL-12 and IL-23 serve as potent mucosal adjuvants when co-presented on whole inactivated influenza vaccines

  2014cited by this paper
• Dendritic Cell-Targeted Vaccines

  2014cited by this paper
• Solid Bioneedle-Delivered Influenza Vaccines Are Highly Thermostable and Induce Both Humoral and Cellular Immune Responses

  2014cited by this paper
• Intranasal H5N1 Vaccines, Adjuvanted with Chitosan Derivatives, Protect Ferrets against Highly Pathogenic Influenza Intranasal and Intratracheal Challenge

  2014cited by this paper
• Antigenic Differences between AS03 Adjuvanted Influenza A (H1N1) Pandemic Vaccines: Implications for Pandemrix-Associated Narcolepsy Risk

  2014cited by this paper
• Altered Peptide Ligands Revisited: Vaccine Design through Chemically Modified HLA-A2–Restricted T Cell Epitopes

  2014cited by this paper
• Influenza T-cell Epitope-Loaded Virosomes Adjuvanted with CpG as a Potential Influenza Vaccine

  2014cited by this paper
• Different Arms of the Adaptive Immune System Induced by a Combination Vaccine Work in Concert to Provide Enhanced Clearance of Influenza

  2014cited by this paper
• Liposomes as vaccine delivery systems: a review of the recent advances

  2014cited by this paper
• Priming by a novel universal influenza vaccine (Multimeric-001)-a gateway for improving immune response in the elderly population.

  2014cited by this paper
• Cationic Liposomes Loaded with a Synthetic Long Peptide and Poly(I:C): a Defined Adjuvanted Vaccine for Induction of Antigen-Specific T Cell Cytotoxicity

  2014cited by this paper
• Potent adjuvant effects of novel NKT stimulatory glycolipids on hemagglutinin based DNA vaccine for H5N1 influenza virus.

  2014cited by this paper
• Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses.

  2014cited by this paper
• Intranasal chitosan-DNA vaccines that protect across influenza virus subtypes.

  2014cited by this paper
• T Cell Responses to Viral Infections – Opportunities for Peptide Vaccination

  2014cited by this paper
• Molecular mechanisms of T cell co-stimulation and co-inhibition

  2013cited by this paper
• Critical Role of TLR7 Signaling in the Priming of Cross-Protective Cytotoxic T Lymphocyte Responses by a Whole Inactivated Influenza Virus Vaccine

  2013cited by this paper
• Engineering of papaya mosaic virus (PapMV) nanoparticles with a CTL epitope derived from influenza NP

  2013cited by this paper
• Rapidly produced SAM® vaccine against H7N9 influenza is immunogenic in mice

  2013cited by this paper
• Immunogenicity and protective efficacy of candidate universal influenza A nanovaccines produced in plants by Tobacco mosaic virus-based vectors.

  2013cited by this paper
• Stability of whole inactivated influenza virus vaccine during coating onto metal microneedles.

  2013cited by this paper
• AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial.

  2013cited by this paper
• Long-term immunogenicity of two doses of 2009 A/H1N1v vaccine with and without AS03A adjuvant in HIV-1-infected adults

  2013cited by this paper
• Biodistribution of vaccines comprised of hydrophobically-modified poly(γ-glutamic acid) nanoparticles and antigen proteins using fluorescence imaging.

  2013cited by this paper
• The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns.

  2013cited by this paper
• Formulation optimization of itraconazole loaded PEGylated liposomes for parenteral administration by using design of experiments.

  2013cited by this paper
• Therapeutic Vaccination Using Cationic Liposome-Adjuvanted HIV Type 1 Peptides Representing HLA-Supertype-Restricted Subdominant T Cell Epitopes: Safety, Immunogenicity, and Feasibility in Guinea-Bissau

  2013cited by this paper
• Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies

  2013cited by this paper
• An M2e-based synthetic peptide vaccine for influenza A virus confers heterosubtypic protection from lethal virus challenge

  2013cited by this paper
• Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE+GLA) adjuvant.

  2013cited by this paper
• The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly.

  2013cited by this paper
• Emulsified Phosphatidylserine, Simple and Effective Peptide Carrier for Induction of Potent Epitope-Specific T Cell Responses

  2013cited by this paper
• A recombinant viruslike particle influenza A (H7N9) vaccine.

  2013cited by this paper
• Evaluation of 2009 pandemic H1N1 influenza vaccination in adults with lymphoid malignancies receiving chemotherapy or following autologous stem cell transplant

  2013cited by this paper
• Improved adjuvanting of seasonal influenza vaccines: Preclinical studies of MVA‐NP+M1 coadministration with inactivated influenza vaccine

  2013cited by this paper
• A case-study investigating the physicochemical characteristics that dictate the function of a liposomal adjuvant

  2013cited by this paper
• Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study

  2013cited by this paper
• The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect.

  2013cited by this paper
• Localized mucosal response to intranasal live attenuated influenza vaccine in adults.

  2013cited by this paper
• Preclinical evaluation of Vaxfectin®-adjuvanted Vero cell-derived seasonal split and pandemic whole virus influenza vaccines

  2013cited by this paper
• Clinical Assessment of a Novel Recombinant Simian Adenovirus ChAdOx1 as a Vectored Vaccine Expressing Conserved Influenza A Antigens

  2013cited by this paper
• Advax™, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses.

  2012cited by this paper
• Towards tailored vaccine delivery: needs, challenges and perspectives.

  2012cited by this paper
• Hyperbranched polyglycerols as trimodal imaging agents: design, biocompatibility, and tumor uptake.

  2012cited by this paper
• Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic influenza vaccine containing Advax™ polysaccharide adjuvant.

  2012cited by this paper
• Increased Incidence and Clinical Picture of Childhood Narcolepsy following the 2009 H1N1 Pandemic Vaccination Campaign in Finland

  2012cited by this paper
• Cationic liposomes as adjuvants for influenza hemagglutinin: more than charge alone.

  2012cited by this paper
• A T Cell-Inducing Influenza Vaccine for the Elderly: Safety and Immunogenicity of MVA-NP+M1 in Adults Aged over 50 Years

  2012cited by this paper
• Recombinant protein vaccines produced in insect cells

  2012cited by this paper
• Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection

  2012cited by this paper
• A Virus-Like Particle That Elicits Cross-Reactive Antibodies to the Conserved Stem of Influenza Virus Hemagglutinin

  2012cited by this paper
• Regulatory, biosafety and safety challenges for novel cells as substrates for human vaccines.

  2012cited by this paper
• Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response.

  2012cited by this paper
• Early Priming Minimizes the Age-Related Immune Compromise of CD8+ T Cell Diversity and Function

  2012cited by this paper
• Safety and Immunogenicity of Multimeric-001—a Novel Universal Influenza Vaccine

  2012cited by this paper
• Fluzone® Intradermal vaccine: a promising new chance to increase the acceptability of influenza vaccination in adults

  2012cited by this paper
• Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens.

  2012cited by this paper
• Focused Magnetic Stem Cell Targeting to the Retina Using Superparamagnetic Iron Oxide Nanoparticles

  2012cited by this paper
• Poor seroprotection but allosensitization after adjuvanted pandemic influenza H1N1 vaccine in kidney transplant recipients

  2012cited by this paper
• Survey of the prevalence of immunization non-compliance due to needle fears in children and adults.

  2012cited by this paper
• Synthetic Influenza vaccine (FLU-v) stimulates cell mediated immunity in a double-blind, randomised, placebo-controlled Phase I trial.

  2012cited by this paper
• Elicitation of Broadly Neutralizing Influenza Antibodies in Animals with Previous Influenza Exposure

  2012cited by this paper
• A/H5N1 Prepandemic Influenza Vaccine (Whole Virion, Vero Cell-Derived, Inactivated) [Vepacel®]

  2012cited by this paper
• Dendritic cell-based in vitro assays for vaccine immunogenicity

  2012cited by this paper
• DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials

  2011cited by this paper
• Influenza virosomes as a vaccine adjuvant and carrier system

  2011cited by this paper
• A new intranasal influenza vaccine based on a novel polycationic lipid-ceramide carbamoyl-spermine (CCS). II. Studies in mice and ferrets and mechanism of adjuvanticity.

  2011cited by this paper
• Sublingual Immunization with M2-Based Vaccine Induces Broad Protective Immunity against Influenza

  2011cited by this paper
• Meta-Analysis of the Immunogenicity and Tolerability of Pandemic Influenza A 2009 (H1N1) Vaccines

  2011cited by this paper
• Induction of Virus-Specific Cytotoxic T Lymphocytes as a Basis for the Development of Broadly Protective Influenza Vaccines

  2011cited by this paper
• CAF01 Potentiates Immune Responses and Efficacy of an Inactivated Influenza Vaccine in Ferrets

  2011cited by this paper
• The role of surface charge density in cationic liposome-promoted dendritic cell maturation and vaccine-induced immune responses

  2011cited by this paper
• Response of MUTZ-3 dendritic cells to the different components of the Haemophilus influenzae type B conjugate vaccine: towards an in vitro assay for vaccine immunogenicity.

  2011cited by this paper
• Cross-Protective Peptide Vaccine against Influenza A Viruses Developed in HLA-A*2402 Human Immunity Model

  2011cited by this paper
• Delta inulin polysaccharide adjuvant enhances the ability of split-virion H5N1 vaccine to protect against lethal challenge in ferrets.

  2011cited by this paper
• Immunogenicity and safety of pandemic influenza A (H1N1) 2009 vaccine: systematic review and meta‐analysis

  2011cited by this paper
• Potent CD8+ T-Cell Immunogenicity in Humans of a Novel Heterosubtypic Influenza A Vaccine, MVA−NP+M1

  2011cited by this paper
• Trivalent and quadrivalent MF59(®)-adjuvanted influenza vaccine in young children: a dose- and schedule-finding study.

  2011cited by this paper
• Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age.

  2011cited by this paper
• An international technology platform for influenza vaccines.

  2011cited by this paper
• Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults.

  2011cited by this paper
• Immunogenicity and safety of inactivated influenza vaccines in primed populations: a systematic literature review and meta-analysis.

  2011cited by this paper
• PCPP-formulated H5N1 influenza vaccine displays improved stability and dose-sparing effect in lethal challenge studies.

  2011cited by this paper
• Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial.

  2011cited by this paper

• REAL-TIME AT-LINE MONITORING OF INFLUENZA VIRUS IN CELL CULTURE BY A SURFACE PLASMON RESONANCE BIOSENSOR

  2023cites this paper
• Aprotinin—Drug against Respiratory Diseases

  2023cites this paper
• The Effect of Drugs with α-Glutamyl–Tryptophan for Cytokine Secretion and Level of Surface Molecule ICAM-1 In Vitro

  2023cites this paper
• An ELISA-based assay for determining haemagglutinin potency in egg, cell, or recombinant protein derived influenza vaccines

  2023cites this paper
• Revisiting live attenuated influenza vaccine efficacy among children in developing countries.

  2023cites this paper
• High Clinical Burden of Influenza Disease in Adults Aged ≥ 65 Years: Can We Do Better? A Systematic Literature Review

  2023cites this paper
• Emerging antiviral therapies and drugs for the treatment of influenza

  2022cites this paper
• A Virion-Based Combination Vaccine Protects against Influenza and SARS-CoV-2 Disease in Mice

  2022cites this paper
• Various vaccine platforms in the field of COVID-19

  2022cites this paper
• Hemagglutinin‐based DNA vaccines containing trimeric self‐assembling nanoparticles confer protection against influenza

  2022cites this paper
• An Overview of Vaccine Adjuvants: Current Evidence and Future Perspectives

  2022cites this paper
• Influenza Vaccine: An Engineering Vision from Virological Importance to Production

  2022influential citation
• A single-shot vaccine approach for the universal influenza A vaccine candidate M2e

  2022cites this paper
• Nucleic Acids for Potential Treatment of Rheumatoid Arthritis.

  2022cites this paper
• Chemical scaffold recycling: Structure-guided conversion of an HIV integrase inhibitor into a potent influenza virus RNA-dependent RNA polymerase inhibitor designed to minimize resistance potential.

  2022cites this paper
• Dendritic cell activation by a micro particulate based system containing the influenza matrix-2 protein virus-like particle (M2e VLP).

  2022cites this paper
• Greater Breadth of Vaccine-Induced Immunity in Females than Males Is Mediated by Increased Antibody Diversity in Germinal Center B Cells

  2022cites this paper
• “Don’t Look Up” Your Science—Herd Immunity or Herd Mentality?

  2022cites this paper
• Vaccination against Influenza among Health Care Workers in Al Mashaer during Hajj 2019 (1440 H); Uptake and Barriers

  2022cites this paper
• Influenza-Induced CD103+ T Resident Memory Cells Exhibit Enhanced Functional Avidity over CD103− Memory T Cells in the Mediastinal Lymph Node

  2022cites this paper
• Characterization of Classical Vaccines by Charge Detection Mass Spectrometry.

  2021cites this paper
• Modification of the Spike Protein for Vaccines against Enveloped RNA Viruses

  2021cites this paper
• Brief exposure of skin to near-infrared laser augments early vaccine responses

  2021cites this paper
• Synthesis and Study of a New Type of Nonanionic Demulsifier for Chemical Flooding Emulsion Demulsification

  2021cites this paper
• Whole-Cell Vaccine Preparation: Options and Perspectives.

  2021cites this paper
• Regulatory roles of galectins on influenza A virus and their potential as a therapeutic strategy.

  2021cites this paper
• An Overview of Influenza Viruses and Vaccines

  2021cites this paper
• Animal Models Utilized for the Development of Influenza Virus Vaccines

  2021influential citation
• Natural killer cells contribute to enhanced respiratory disease after oil-in-water emulsion adjuvanted vaccination against respiratory syncytial virus and infection

  2021cites this paper
• Influenza Vaccination for the Prevention of Cardiovascular Disease in the Americas: Consensus document of the Inter-American Society of Cardiology and the Word Heart Federation

  2021cites this paper
• An Antigenic Thrift-Based Approach to Influenza Vaccine Design

  2021influential citation
• Efficacy of recombinant NP-M1 and NP-M1-CRT DNA vaccines against Influenza A viruses in mice C57/BL6

  2021cites this paper
• Influenza vaccines: Past, present, and future

  2021cites this paper
• Downstream processing for influenza vaccines and candidates: An update

  2021cites this paper
• Selecting and Using the Appropriate Influenza Vaccine for Each Individual

  2021cites this paper
• Next-Generation Influenza HA Immunogens and Adjuvants in Pursuit of a Broadly Protective Vaccine

  2021cites this paper
• DNA vaccine targeting the ectodomain of influenza M2 protein to endolysosome pathway enhances anti-M2e protective antibody response in mice.

  2021cites this paper
• Cell-based influenza vaccine: current production, halal status assessment, and recommendations towards Islamic-compliant manufacturing

  2021cites this paper
• Establishment of a genetically engineered chicken DF-1 cell line for efficient amplification of influenza viruses in the absence of trypsin

  2021cites this paper
• CAvant® WO-60 as an Effective Immunological Adjuvant for Avian Influenza and Newcastle Disease Vaccine

  2021cites this paper
• Single-Cell Analysis of Antigen-Specific CD8+ T-Cell Transcripts Reveals Profiles Specific to mRNA or Adjuvanted Protein Vaccines

  2021cites this paper
• The Pre-Existing Human Antibody Repertoire to Computationally Optimized Influenza H1 Hemagglutinin Vaccines

  2021cites this paper
• The Effects of Vaccination in Case of Influenza on the Elderly in Hong Kong in Reducing Flu Infection

  2021cites this paper
• The 2020 race towards SARS-CoV-2 specific vaccines

  2021cites this paper
• The Antiviral Role of Galectins toward Influenza A Virus Infection—An Alternative Strategy for Influenza Therapy

  2021cites this paper
• Influenza viral particles harboring the SARS-CoV-2 spike RBD as a combination respiratory disease vaccine

  2021cites this paper
• Protective cellular and mucosal immune responses following nasal administration of a whole gamma-irradiated influenza A (subtype H1N1) vaccine adjuvanted with interleukin-28B in a mouse model

  2021cites this paper
• Neutrophils and Influenza: A Thin Line between Helpful and Harmful

  2021cites this paper
• Virosome-based nanovaccines; a promising bioinspiration and biomimetic approach for preventing viral diseases: A review

  2021cites this paper
• A formulated poly (I:C)/CCL21 as an effective mucosal adjuvant for gamma-irradiated influenza vaccine

  2021cites this paper
• Preparation and characterization of nanocurcumin based hybrid virosomes as a drug delivery vehicle with enhanced anticancerous activity and reduced toxicity

  2021cites this paper
• Efficacy of recombinant NPM 1 and NPM 1-CRT 3 DNA vaccines against Influenza A viruses in mice 4 C 57 / BL 6 5

  2021cites this paper
• Immune Responses to Pandemic H1N1 Influenza Virus Infection in Pigs Vaccinated with a Conserved Hemagglutinin HA1 Peptide Adjuvanted with CAF®01 or CDA/αGalCerMPEG

  2021cites this paper
• Advances in Development and Application of Influenza Vaccines

  2021cites this paper
• Investigating the Interaction between Negative Strand RNA Viruses and Their Hosts for Enhanced Vaccine Development and Production

  2021cites this paper
• [Vaccination against community acquired pneumonia in adults. Update 2021 of the position paper by Neumoexpertos en Prevención Group].

  2021cites this paper
• Heterologous viral protein interactions within licensed seasonal influenza virus vaccines

  2020cites this paper
• Regional differences in vaccine uptake and serological responses to vaccine and circulating strains of H1N1 viruses among patients with confirmed influenza

  2020cites this paper
• Construction of an Escherichia coli expression vector for the non-structural (NS)-1 protein of avian infuenza virus H5N1

  2020cites this paper
• Semisynthetic Cardenolides Acting as Antiviral Inhibitors of Influenza A Virus Replication by Preventing Polymerase Complex Formation

  2020cites this paper
• Fitness of influenza A and B viruses with reduced susceptibility to baloxavir: A mini‐review

  2020cites this paper
• Impact of Protein Glycosylation on the Design of Viral Vaccines.

  2020cites this paper
• Inhibitory effects of aprotinin on influenza A and B viruses in vitro and in vivo

  2020cites this paper
• Development of PLGA-PEG-PLGA Hydrogel Delivery System for Enhanced Immunoreaction and Efficacy of Newcastle Disease Virus DNA Vaccine

  2020cites this paper
• Response to a DNA vaccine against the H5N1 virus depending on the chicken line and number of doses

  2020cites this paper
• Pharmacodynamic and safety considerations for influenza vaccine and adjuvant design

  2020cites this paper
• Host Protective Immune Responses against Influenza A Virus Infection

  2020cites this paper
• SARS-CoV-2 reinfection and implications for vaccine development

  2020cites this paper
• Quantifying memory CD8 T cell-mediated immune pressure on influenza A virus infection in vivo

  2020cites this paper
• Biopharmaceutical molecules

  2020cites this paper
• Quercetin as a Natural Therapeutic Candidate for the Treatment of Influenza Virus

  2020cites this paper
• Efforts to Improve the Seasonal Influenza Vaccine

  2020cites this paper
• The Kaposi’s Sarcoma-Associated Herpesvirus (KSHV) gH/gL Complex Is the Predominant Neutralizing Antigenic Determinant in KSHV-Infected Individuals

  2020cites this paper
• Type IIb Heat Labile Enterotoxin B Subunit as a Mucosal Adjuvant to Enhance Protective Immunity against H5N1 Avian Influenza Viruses

  2020cites this paper
• Evaluation of Self-Adjuvanting M2e Vaccine Efficacy in Response to Influenza A Virus Challenge

  2020cites this paper
• Next-generation influenza vaccines: opportunities and challenges

  2020cites this paper
• Matrix Protein 2 Extracellular Domain-Specific Monoclonal Antibodies Are an Effective and Potentially Universal Treatment for Influenza A

  2020cites this paper
• MicroRNA‐206 inhibits influenza A virus replication by targeting tankyrase 2

  2020cites this paper
• Emerging Role of Mucosal Vaccine in Preventing Infection with Avian Influenza A Viruses

  2020cites this paper
• Influenza-Specific Lung-Resident Memory CD8+ T Cells.

  2020cites this paper
• Immunogenicity, Safety, and Efficacy of a Standalone Universal Influenza Vaccine, FLU-v, in Healthy Adults

  2020influential citation
• Novel calixarene-based surfactant enables low dose split inactivated vaccine protection against influenza infection.

  2020cites this paper
• Influenza A and B viruses with reduced baloxavir susceptibility display attenuated in vitro fitness but retain ferret transmissibility

  2020cites this paper
• miR‐193b represses influenza A virus infection by inhibiting Wnt/β‐catenin signalling

  2019cites this paper
• Immunity to Influenza: Closing in on a Moving Target

  2019cites this paper
• Development of a Universal Influenza Vaccine

  2019cites this paper
• Human cell-based in vitro systems for vaccine evaluation

  2019cites this paper
• Antiviral potential of human IFN-α subtypes against influenza A H3N2 infection in human lung explants reveals subtype-specific activities

  2019cites this paper
• Development of Universal Influenza Vaccines Targeting Conserved Viral Proteins

  2019cites this paper
• Licensing the first reduced, 6 µg dose whole virion, aluminum adjuvanted seasonal influenza vaccine - A randomized-controlled multicenter trial.

  2019cites this paper
• Antiviral Activities of Hibiscus sabdariffa L. Tea Extract Against Human Influenza A Virus Rely Largely on Acidic pH but Partially on a Low-pH-Independent Mechanism

  2019cites this paper
• Development of a universal influenza vaccine using hemagglutinin stem protein produced from Pichia pastoris.

  2019cites this paper
• Microarray Gene Expression Dataset Re-analysis Reveals Variability in Influenza Infection and Vaccination

  2019cites this paper
• Delayed-Onset Anaphylaxis Caused by IgE Response to Influenza Vaccination

  2019cites this paper
• Étude de la résistance des virus influenza B contemporains aux inhibiteurs de la neuraminidase et son impact sur le fitness viral

  2019cites this paper
• Intragastric delivery of recombinant Lactococcus lactis displaying ectodomain of influenza matrix protein 2 (M2e) and neuraminidase (NA) induced focused mucosal and systemic immune responses in chickens.

  2019cites this paper
• Sequential DNA immunization of chickens with bivalent heterologous vaccines induce highly reactive and cross‐specific antibodies against influenza hemagglutinin

  2019cites this paper
• Influenza virus-specific CD4+ and CD8+ T cell-mediated immunity induced by infection and vaccination.

  2019cites this paper
• AuNP-M2e + sCpG vaccination of juvenile mice generates lifelong protective immunity to influenza A virus infection

  2019cites this paper
• Techniques Employed in Production of Traditional Vaccines Commonly Used by Military Forces: A Review

  2019cites this paper